As of Nov 21
| +0.0701 / +0.80%|
The 3 analysts offering 12-month price forecasts for Arcturus Therapeutics Ltd have a median target of 2.00, with a high estimate of 2.00 and a low estimate of 1.00. The median estimate represents a -77.45% decrease from the last price of 8.87.
The current consensus among 3 polled investment analysts is to Outperform stock in Arcturus Therapeutics Ltd. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.